Clinical trials: in Guatemala
Diabetes Mellitus, Type 2, Acute Coronary Syndrome
Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome
The purpose of this study is to evaluate the cardiovascular outcomes of alogliptin, once daily (QD), compared with placebo, in addition to standard of care, in patients with type 2 diabetes mellitus and acute coronary syndrome.
- Trial name
- EXAMINE (NCT00968708)
- Testing
- Alogliptin
- Where
- 908 sites in United States, Argentina and 48 more
- Volunteers
- 5,380 people
- Sponsor
- Takeda
Chronic Obstructive Pulmonary Disease
Efficacy, Safety, and Tolerability of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)
This study compared the efficacy and safety of NVA237 with tiotropium in patients with moderate to severe COPD. Tiotropium belongs to the same drug class as NVA237.
- Trial name
- GLOW5 (NCT01613326)
- Testing
- NVA237, Tiotropium, salbutamol/albuterol
- Where
- 77 sites in Canada, Croatia and 13 more
- Volunteers
- 657 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes Mellitus, Cardiovascular Disease
Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases)
The purpose of this study was to determine whether, in patients with type 2 diabetes and pre-existing disease of the heart and the circulatory system and/or the kidney, aliskiren at a target dose of 300 mg once daily (compared to…
- Trial name
- ALTITUDE (NCT00549757)
- Testing
- Aliskiren
- Where
- 776 sites in United States, Argentina and 35 more
- Volunteers
- 8,606 people
- Sponsor
- Novartis Pharmaceuticals
Acute Gout
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study
The purpose of the 12-week core study was to demonstrate that canakinumab given upon acute gout flares relieves the signs and symptoms and prevents recurrence of gout flares in patients with frequent flares of gout for whom…
- Trial name
- β-RELIEVED (NCT01029652)
- Testing
- Canakinumab 150 mg, Triamcinolone acetonide 40 mg
- Where
- 47 sites in Australia, Belgium and 15 more
- Volunteers
- 230 people
- Sponsor
- Novartis Pharmaceuticals
Diarrhea., Pneumonia.
The Effectiveness of Co-packaging With Zinc to Improve Treatment of Diarrhea and Pneumonia in Guatemala
This project applies a randomized community design to test the effectiveness of health center level co-packaging and counseling messages to improve provider and caregiver behavior in the treatment of diarrhea with zinc \& oral…
- Trial name
- Zinc10 (NCT02044107)
- Testing
- Co-packaging and counseling messages
- Where
- Guatemala
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- Center for Studies of Sensory Impairment, Aging and Metabolism
Nutrition, Pregnancy
Randomized Placebo-Controlled Trial (RPCT) of Maize/Zinc in Guatemala
Malnutrition is a serious health problem in the developing world. This study looks at the effects of changing the type of basic food staple (corn) used in Guatemala and infant zinc supplementation on infants' growth, development…
- Trial name
- NCT00098202
- Testing
- Low phytic acid maize, Zinc
- Where
- Guatemala
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- NICHD Global Network for Women's and Children's Health
Metastatic Breast Cancer
A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1)
This is a Phase III, multicenter, randomized, placebo-controlled trial designed to evaluate the efficacy and safety of bevacizumab in combination with chemotherapy compared with chemotherapy alone in subjects with previously…
- Trial name
- NCT00262067
- Testing
- Bevacizumab, Chemotherapy
- Where
- 92 sites in United States, Australia and 20 more
- Volunteers
- 1,237 people
- Sponsor
- Genentech, Inc.
Type 2 Diabetes Mellitus
Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to determine the safety and effectiveness of adding alogliptin, once daily (QD), compared to glipizide with metformin in diabetic patients.
- Trial name
- ENDURE (NCT00856284)
- Testing
- Alogliptin, Metformin, Glipizide
- Where
- 261 sites in United States, Argentina and 30 more
- Volunteers
- 2,639 people
- Sponsor
- Takeda
Complementary Feeding, Infant Growth
First Bites: Complementary Feeding - A Global Network Cluster Randomized Controlled Trial
The specific aims of this project is to determine the impact of a daily intake of one half ounce of lyophilized meat between 6-18 months of age (0.5 oz for 6-12 mo; 0.75 oz for 12-18 mo) on linear growth velocity, zinc and iron…
- Trial name
- First Bites (NCT01084109)
- Testing
- Lyophilized meat, Cereal
- Where
- 4 sites in Guatemala, Pakistan and 2 more
- Volunteers
- 1,236 people, healthy volunteers welcome
- Sponsor
- NICHD Global Network for Women's and Children's Health
Smoking
GN Tobacco Use Survey
Smoking can contribute to many health problems for mothers and their babies. In developing countries, there is little information about the number of pregnant women that smoke and the reasons why some pregnant women choose to…
- Trial name
- NCT00121368
- Where
- 9 sites in Argentina, Brazil and 6 more
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- NICHD Global Network for Women's and Children's Health
Hand Hygiene Behavior
Understanding Hand Hygiene Behavior at Unidad Nacional Oncologia Pediatrica
Healthcare associated infections increase morbidity and mortality among all hospitalized patients, especially in those who are immunocompromised, in both developed and in countries with limited resources.
- Trial name
- HHFG (NCT01419054)
- Where
- Guatemala
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- St. Jude Children's Research Hospital
Maternal Morbidity and Mortality, Stillbirth and Neonatal Mortality
Emergency Obstetric and Neonatal Care: The EmONC Trial
The objective of this cluster randomized controlled trial is to reduce maternal and neonatal mortality by increasing access to and improving the quality of obstetric and neonatal care for pregnant women in study clusters.
- Trial name
- EmONC (NCT01073488)
- Testing
- Community Mobilization, HBLSS and facility improvement
- Where
- 7 sites in Argentina, Guatemala and 4 more
- Volunteers
- 267,181 people, healthy volunteers welcome
- Sponsor
- NICHD Global Network for Women's and Children's Health
Anemia
A Study of Once-Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Pre-Dialysis Patients Not Currently Treated With ESA.
This single arm study will assess the efficacy and safety of subcutaneous Mircera for the correction and maintenance of hemoglobin levels in predialysis patients with renal anemia who are not currently treated with ESA.
- Trial name
- NCT00680563
- Testing
- methoxy polyethylene glycol-epoetin beta [Mircera]
- Where
- 22 sites in Argentina, Brazil and 8 more
- Volunteers
- 4 people
- Sponsor
- Hoffmann-La Roche
Chronic Obstructive Pulmonary Disease (COPD)
A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to provide pivotal efficacy and safety data for QVA149 in patients with moderate to severe COPD.
- Trial name
- SHINE (NCT01202188)
- Testing
- indacaterol and glycopyrronium (QVA149), glycopyrronium (NVA237), indacaterol (QAB149)
- Where
- 166 sites in United States, Australia and 17 more
- Volunteers
- 2,144 people
- Sponsor
- Novartis Pharmaceuticals
Meningitis, Meningococcal Infection
Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants
The primary objective of this phase 3b study is to evaluate the safety and tolerability of Novartis MenACWY conjugate vaccine when administered with routine infant vaccinations to healthy infants
- Trial name
- NCT00806195
- Testing
- MenACWY-CRM197, DTaP (Diptheria, Tetanus, Pertussis) Vaccine, Hib (Haemophilus influenza b) Vaccine
- Where
- 153 sites in United States, China and 4 more
- Volunteers
- 7,744 people, healthy volunteers welcome
- Sponsor
- Novartis
HIV
TMC114-C211: Trial of an Investigational Protease Inhibitor TMC114 With Ritonavir ("TMC114/r") in HIV-1 Infected Patients Who Have Never Been Treated With Antiretroviral Medications.
The purpose of this study is to compare the efficacy, safety and tolerability of TMC114/r versus Kaletra (a combination pill of lopinavir and ritonavir, ("lpv/rtv") in HIV-1 infected patients who have never been treated with…
- Trial name
- NCT00258557
- Testing
- LPV/RTV, TMC-114/RTV
- Where
- 89 sites in United States, Argentina and 23 more
- Volunteers
- 692 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Diabetes Mellitus, Type 2
The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea)
The purpose of this study is to evaluate the efficacy and safety of 2 different doses of canagliflozin compared with placebo in patients with type 2 diabetes mellitus who are receiving treatment with metformin and sulphonylurea…
- Trial name
- NCT01106625
- Testing
- Canagliflozin, Metformin, Sulphonylruea
- Where
- 76 sites in United States, Australia and 10 more
- Volunteers
- 469 people
- Sponsor
- Janssen Research & Development, LLC
Type 2 Diabetes Mellitus
Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus.
The purpose of this study is to evaluate the safety and efficacy of alogliptin, once daily (QD), taken in combination with pioglitazone in adults with type 2 diabetes mellitus.
- Trial name
- NCT00328627
- Testing
- Alogliptin, Pioglitazone
- Where
- 90 sites in United States, Australia and 17 more
- Volunteers
- 1,554 people
- Sponsor
- Takeda
Diabetes Mellitus
Efficacy of Alogliptin With Pioglitazone (Actos®) in Subjects With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the combination of alogliptin, once daily (QD), and pioglitazone in patients with type 2 diabetes mellitus who are inadequately controlled with diet and exercise alone.
- Trial name
- NCT00395512
- Testing
- Alogliptin, Pioglitazone
- Where
- 161 sites in United States, Argentina and 21 more
- Volunteers
- 655 people
- Sponsor
- Takeda
Diabetes Mellitus
Long-term Safety of Alogliptin in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the long-term safety of alogliptin, once daily (QD), following participation in 1 of 7 controlled studies in patients with type 2 diabetes mellitus.
- Trial name
- NCT00306384
- Testing
- Alogliptin
- Where
- 114 sites in United States, Argentina and 10 more
- Volunteers
- 3,323 people
- Sponsor
- Takeda